Patents by Inventor Toshinori Agatsuma
Toshinori Agatsuma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210238303Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.Type: ApplicationFiled: April 14, 2021Publication date: August 5, 2021Applicants: DAIICHI SANKYO COMPANY, LIMITED, SAPPORO MEDICAL UNIVERSITYInventors: Toshinori AGATSUMA, Shu TAKAHASHI, Jun HASEGAWA, Daisuke OKAJIMA, Hirofumi HAMADA, Miki YAMAGUCHI
-
Patent number: 11008398Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.Type: GrantFiled: January 24, 2019Date of Patent: May 18, 2021Assignees: DAIICHI SANKYO COMPANY, LIMITED, SAPPORO MEDICAL UNIVERSITYInventors: Toshinori Agatsuma, Shu Takahashi, Jun Hasegawa, Daisuke Okajima, Hirofumi Hamada, Miki Yamaguchi
-
Publication number: 20190359722Abstract: Provided is an antibody specific to EPHA2. A monoclonal antibody specifically binding to EPHA2, comprising a heavy chain variable region consisting of the amino acid sequence as set forth in SEQ ID NO: 20 and a light chain variable region consisting of the amino acid sequence as set forth in SEQ ID NO: 22, or a functional fragment of the monoclonal antibody specifically binding to EPHA2, and a monoclonal antibody specifically binding to EPHA2, comprising a heavy chain variable region consisting of the amino acid sequence as set forth in SEQ ID NO: 15 and a light chain variable region consisting of the amino acid sequence as set forth in SEQ ID NO: 18, or a functional fragment of the monoclonal antibody specifically binding to EPHA2.Type: ApplicationFiled: January 22, 2018Publication date: November 28, 2019Applicant: TOYO UNIVERSITYInventors: Kazunori KATO, Toshinori AGATSUMA, Jun HASEGAWA
-
Publication number: 20190144559Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.Type: ApplicationFiled: January 24, 2019Publication date: May 16, 2019Applicants: DAIICHI SANKYO COMPANY, LIMITED, SAPPORO MEDICAL UNIVERSITYInventors: Toshinori Agatsuma, Shu Takahashi, Jun Hasegawa, Daisuke Okajima, Hirofumi Hamada, Miki Yamaguchi
-
Patent number: 10227417Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.Type: GrantFiled: November 22, 2017Date of Patent: March 12, 2019Assignees: DAIICHI SANKYO COMPANY, LIMITED, SAPPORO MEDICAL UNIVERSITYInventors: Toshinori Agatsuma, Shu Takahashi, Jun Hasegawa, Daisuke Okajima, Hirofumi Hamada, Miki Yamaguchi
-
Publication number: 20180094073Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.Type: ApplicationFiled: November 22, 2017Publication date: April 5, 2018Applicants: DAIICHI SANKYO COMPANY, LIMITED, SAPPORO MEDICAL UNIVERSITYInventors: Toshinori AGATSUMA, Shu TAKAHASHI, Jun HASEGAWA, Daisuke OKAJIMA, Hirofumi HAMADA, Miki YAMAGUCHI
-
Patent number: 9850312Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.Type: GrantFiled: June 20, 2016Date of Patent: December 26, 2017Assignees: DAIICHI SANKYO COMPANY, LIMITED, SAPPORO MEDICAL UNIVERSITYInventors: Toshinori Agatsuma, Shu Takahashi, Jun Hasegawa, Daisuke Okajima, Hirofumi Hamada, Miki Yamaguchi
-
Patent number: 9714298Abstract: The present invention provides an antibody which binds to a fibroblast growth factor receptor.Type: GrantFiled: April 9, 2013Date of Patent: July 25, 2017Assignee: Daiichi Sankyo Company, LimitedInventors: Toshiaki Ohtsuka, Chigusa Yoshimura, Toshinori Agatsuma, Atsushi Urano, Takako Kimura, Yumi Matsui, Tatsuji Matsuoka, Jun Hasegawa, Yasuki Kamai, Reimi Kawaida
-
Patent number: 9481733Abstract: The present invention provides an antibody which binds to a fibroblast growth factor receptor.Type: GrantFiled: July 6, 2015Date of Patent: November 1, 2016Assignee: Daiichi Sankyo Company, LimitedInventors: Toshiaki Ohtsuka, Chigusa Yoshimura, Toshinori Agatsuma, Atsushi Urano, Takako Kimura, Yumi Matsui, Tatsuji Matsuoka, Jun Hasegawa, Yasuki Kamai, Reimi Kawaida
-
Publication number: 20160297890Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.Type: ApplicationFiled: June 20, 2016Publication date: October 13, 2016Applicants: DAIICHI SANKYO COMPANY, LIMITED, SAPPORO MEDICAL UNIVERSITYInventors: Toshinori AGATSUMA, Shu TAKAHASHI, Jun HASEGAWA, Daisuke OKAJIMA, Hirofumi HAMADA, Miki YAMAGUCHI
-
Patent number: 9403909Abstract: The present disclosure provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for MST1R, which plays an integral role in various disorders or conditions, such as cancer. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the disclosure also can be used in the diagnostics field, as well as for further investigating the role of MST1R in the progression of disorders associated with tumors. The disclosure also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: GrantFiled: August 10, 2011Date of Patent: August 2, 2016Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Reimi Kawaida, Toshiaki Ohtsuka, Toshinori Agatsuma, Philip Rodley, Sandra Miller, Ulrike Schubert
-
Publication number: 20160031987Abstract: The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc.Type: ApplicationFiled: October 5, 2015Publication date: February 4, 2016Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Jun Hasegawa, Toshiaki Ohtsuka, Atsushi Urano, Junko Yamaguchi, Toshinori Agatsuma, Kaori Nakahara, Takeshi Takizawa
-
Publication number: 20160009820Abstract: The present invention provides an antibody which binds to a fibroblast growth factor receptor.Type: ApplicationFiled: July 6, 2015Publication date: January 14, 2016Applicant: Daiichi Sankyo Company, LimitedInventors: Toshiaki Ohtsuka, Chigusa Yoshimura, Toshinori Agatsuma, Atsushi Urano, Takako Kimura, Yumi Matsui, Tatsuji Matsuoka, Jun Hasegawa, Yasuki Kamai, Reimi Kawaida
-
Patent number: 9150657Abstract: The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc.Type: GrantFiled: May 22, 2013Date of Patent: October 6, 2015Assignee: Daiichi Sankyo Company, LimitedInventors: Jun Hasegawa, Toshiaki Ohtsuka, Atsushi Urano, Junko Yamaguchi, Toshinori Agatsuma, Kaori Nakahara, Takeshi Takizawa
-
Patent number: 9114131Abstract: An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.Type: GrantFiled: October 4, 2011Date of Patent: August 25, 2015Assignee: Daiichi Sankyo Company, LimitedInventors: Ichiro Watanabe, Yoshiharu Hiruma, Eisuke Tsuda, Tatsuji Matsuoka, Toshiaki Ohtsuka, Tohru Takahashi, Toshinori Agatsuma, Sandra Miller, Robert Mühlbacher, Kathrin-Ladetzki Baehs, Steffen Runz, Ulrike Schubert, Ingrid Schuster, Dirk Ponsel
-
Publication number: 20150125454Abstract: The present invention provides an antibody which binds to a fibroblast growth factor receptor.Type: ApplicationFiled: April 9, 2013Publication date: May 7, 2015Applicant: Daiichi Sankyo Company, LimitedInventors: Toshiaki Ohtsuka, Chigusa Yoshimura, Toshinori Agatsuma, Atsushi Urano, Takako Kimura, Yumi Matsui, Tatsuji Matsuoka, Jun Hasegawa, Yasuki Kamai, Reimi Kawaida
-
Publication number: 20140212439Abstract: The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc.Type: ApplicationFiled: May 22, 2013Publication date: July 31, 2014Applicant: Daiichi Sankyo Company, LimitedInventors: Jun Hasegawa, Toshiaki Ohtsuka, Atsushi Urano, Junko Yamaguchi, Toshinori Agatsuma, Kaori Nakahara, Takeshi Takizawa
-
Publication number: 20130280276Abstract: An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.Type: ApplicationFiled: October 4, 2011Publication date: October 24, 2013Inventors: Ichiro Watanabe, Yoshiharu Hiruma, Eisuke Tsuda, Tatsuji Matsuoka, Toshiaki Ohtsuka, Tohru Takahashi, Toshinori Agatsuma, Sandra Miller, Robert Mühlbacher, Kathrin-Ladetzki Baehs, Steffen Runz, Ulrike Schubert, Ingrid Schuster, Dirk Ponsel
-
Patent number: 8449882Abstract: Problem to Be Solved It is intended to provide an antibody having an inhibitory activity against cell malignant transformation and/or tumor cell growth, etc. Solution The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc.Type: GrantFiled: February 25, 2010Date of Patent: May 28, 2013Assignee: Daiichi Sankyo Company, LimitedInventors: Jun Hasegawa, Toshiaki Ohtsuka, Atsushi Urano, Junko Yamaguchi, Toshinori Agatsuma, Kaori Nakahara, Takeshi Takizawa
-
Publication number: 20120034215Abstract: The present disclosure provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for MST1R, which plays an integral role in various disorders or conditions, such as cancer. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the disclosure also can be used in the diagnostics field, as well as for further investigating the role of MST1R in the progression of disorders associated with tumors. The disclosure also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: August 10, 2011Publication date: February 9, 2012Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Reimi Kawaida, Toshiaki Ohtsuka, Toshinori Agatsuma, Philip Rodley, Sandra Miller, Ulrike Schubert